211 related articles for article (PubMed ID: 34962030)
21. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
[TBL] [Abstract][Full Text] [Related]
22. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
23. Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis.
Zhang R; Li T; Wang W; Gan W; Lv S; Zeng Z; Hou Y; Yan Z; Yang M
Front Oncol; 2020; 10():594098. PubMed ID: 33425745
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.
Zhang ML; Kem M; Mooradian MJ; Eliane JP; Huynh TG; Iafrate AJ; Gainor JF; Mino-Kenudson M
Mod Pathol; 2019 Apr; 32(4):511-523. PubMed ID: 30367104
[TBL] [Abstract][Full Text] [Related]
25. Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Mandarano M; Bellezza G; Belladonna ML; Vannucci J; Gili A; Ferri I; Lupi C; Ludovini V; Falabella G; Metro G; Mondanelli G; Chiari R; Cagini L; Stracci F; Roila F; Puma F; Volpi C; Sidoni A
Front Immunol; 2020; 11():839. PubMed ID: 32536910
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Rosenbaum MW; Gigliotti BJ; Pai SI; Parangi S; Wachtel H; Mino-Kenudson M; Gunda V; Faquin WC
Endocr Pathol; 2018 Mar; 29(1):59-67. PubMed ID: 29372535
[TBL] [Abstract][Full Text] [Related]
27. Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.
Ma WJ; Wang X; Yan WT; Zhou ZG; Pan ZZ; Chen G; Zhang RX
World J Gastroenterol; 2018 May; 24(20):2181-2190. PubMed ID: 29853736
[TBL] [Abstract][Full Text] [Related]
28. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
[TBL] [Abstract][Full Text] [Related]
29. Basal-subtype bladder tumours show a 'hot' immunophenotype.
Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
[TBL] [Abstract][Full Text] [Related]
30. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
Holland BC; Sood A; Delfino K; Dynda DI; Ran S; Freed N; Alanee S
Cancer Immunol Immunother; 2019 Jun; 68(6):991-997. PubMed ID: 30997535
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
Sue-A-Quan R; Patel PG; Shakfa N; Nyi MN; Afriyie-Asante A; Kang EY; Köbel M; Koti M
Gynecol Oncol; 2021 Aug; 162(2):421-430. PubMed ID: 34088514
[TBL] [Abstract][Full Text] [Related]
32. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
[TBL] [Abstract][Full Text] [Related]
33. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
[TBL] [Abstract][Full Text] [Related]
34. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
[TBL] [Abstract][Full Text] [Related]
35. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
36. Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder.
Wang B; Xie S; Bi J; Liu Z; Zeng H; Huang H; Xue M; He Z; Yang M; Yu H; Huang J; Lin T
Histopathology; 2019 Sep; 75(3):354-364. PubMed ID: 30653702
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma.
Kawashima A; Kanazawa T; Jingushi K; Kato T; Ujike T; Nagahara A; Fujita K; Morimoto-Okazawa A; Iwahori K; Uemura M; Imamura R; Wada H; Nonomura N
Clin Genitourin Cancer; 2019 Apr; 17(2):114-124. PubMed ID: 30555025
[TBL] [Abstract][Full Text] [Related]
38. Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
Liang C; Peng L; Zeng S; Zhao Q; Tang L; Jiang X; Zhang J; Yan N; Chen Y
Exp Eye Res; 2019 Apr; 181():112-119. PubMed ID: 30639792
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoints indoleamine 2,3-dioxygenase 1 and programmed death-ligand 1 in oral mucosal dysplasia.
Sieviläinen M; Passador-Santos F; Almahmoudi R; Christopher S; Siponen M; Toppila-Salmi S; Salo T; Al-Samadi A
J Oral Pathol Med; 2018 Sep; 47(8):773-780. PubMed ID: 29851145
[TBL] [Abstract][Full Text] [Related]
40. Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis.
Stakhovskyi O; Kobyliak N; Voylenko O; Stakhovskyi E; Ponomarchuk R; Sulaieva O
Cells; 2022 May; 11(11):. PubMed ID: 35681497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]